People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
The data on Novo's Wegovy pill suggests that patients may not need to take weekly injections forever, but can instead opt for more convenient treatments.
People who switched to Novo's Wegovy pill from obesity injections continued to lose weight in a real-world study. According to CNBC, this suggests that patients may not need to take weekly injections forever and can opt for more convenient treatments.
The effectiveness of obesity treatments is being explored in various studies. Researchers published late-stage clinical trial data for retatrutide, an obesity drug, in Ars Technica and Ars Technica Health. The trial included 2,339 participants from 131 clinical trial sites in 11 countries. Participants taking the highest retatrutide dose lost an average of 25 percent of their body weight after 80 weeks and 30 percent after an extension period to 104 weeks. More than a third of participants taking retatrutide lost 30 percent or more of their weight.
Novo is also involved in licensing deals for obesity treatments. According to STAT News, Novo agreed to pay up to $2.6 billion to license an experimental, weekly weight loss pill from China’s Hengrui Pharma. Additionally, BioPharma Dive reported that Novo acquired a challenger to Lilly’s market-leading Zepbound.
Brief written by urgent.news from CNBC, Ars Technica, Ars Technica Health, BioPharma Dive, STAT News — 5 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
